Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avenue TherapeuticsATXI -15.11%34 EV-to-EBIT is 0.53 as of Aug. 09, 2026, which is 17% below its 10-year median of 0.64. GuruFocus rates ATXI with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 372 Biotechnology companies, Avenue Therapeutics ranks better than 84.14% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Avenue Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-1.46 Mil.
Avenue Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics EV-to-EBIT Related Terms
Avenue Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Avenue Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avenue Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avenue Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Avenue Therapeutics's EV-to-EBIT falls into.
Avenue Therapeutics's current Enterprise Value is $-1.10 Mil.
Avenue Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avenue Therapeutics (ATXI) has a EV-to-EBIT of 0.53 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avenue Therapeutics and its competitors. This is 17% below median its historical median of 0.64. Over the past decade, Avenue Therapeutics' EV-to-EBIT has ranged from 0.12 to 0.77. According to the industry distribution chart, Avenue Therapeutics ranks #59 out of 372 companies in the Biotechnology industry, placing it in the top 15.9%.
Is Avenue Therapeutics' EV-to-EBIT too high?
Avenue Therapeutics' current EV-to-EBIT of 0.53 is 17% below median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.77. The Biotechnology industry median EV-to-EBIT is 15.49. Avenue Therapeutics' value of 0.53 is 96.6% below this industry median. Based on the distribution chart, Avenue Therapeutics ranks #59 out of 372 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avenue Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' EV-to-EBIT compare to LYRA and ZVSA?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #59 out of 372 companies for EV-to-EBIT. This places Avenue Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.49. Avenue Therapeutics' value of 0.53 is 96.6% below this benchmark. Historically, Avenue Therapeutics' own EV-to-EBIT has ranged from 0.12 to 0.77 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 15.49, Avenue Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.49, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avenue Therapeutics's current EV-to-EBIT of 0.53 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avenue Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avenue Therapeutics's current EV-to-EBIT is 0.53, which is 17% below median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current EV-to-EBIT of 0.53. The current EV-to-EBIT is 0.53, which is 17% below median its 10-year median of 0.64 and 96.6% below the Biotechnology industry median of 15.49. Avenue Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current EV-to-EBIT is 0.53 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
34GF Score
Get the complete analysis for ATXI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATXI has been successfully added to your 
